Navigation Links
Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule
Date:2/17/2011

ho Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K f
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
2. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Speaks at 16th Annual PBMI Drug Benefit Conference
3. Echo Therapeutics Announces Appointments to Board of Directors
4. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
5. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
6. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
7. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
8. Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum
9. NewCardio Study of QTinno Accuracy Selected for Presentation at the National Scientific Meeting of the American Society of Clinical Pharmacology and Therapeutics
10. DSM and NKT Therapeutics Sign Contract for Lead Product Development and Manufacture
11. JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ACRX ... and commercialization of innovative therapies for the treatment of ... for Zalviso remains July 27, 2014.  The ... the Food and Drug Administration (FDA) had approved Zalviso.  ... notification to the company from the FDA regarding the ...
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
(Date:7/25/2014)... Florida Hospital and MOSI officially announced a transformational ... to come and make a difference in the Tampa Bay ... check to provide the support needed to keep the science ... transform the IMAX Dome Theatre from film to a state-of-the-art ... Dome Theatre in the state of Florida, and it is ...
(Date:7/25/2014)... -- The human brain can preserve oxygen to protect ... finds. Although dehydration significantly reduces blood flow ... the brain compensates by increasing the amount of oxygen ... helped us understand a lot more about how the ... study first author Steven Trangmar, a researcher at Brunel ...
(Date:7/25/2014)... 25, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Ibuprofen and Oxcarbazepine Tablets . ... lot of Ibuprofen and one lot of Oxcarbazepine Tablets, by ... mislabeled packaging. Oxcarbazepine is used for the treatment of certain ... The reason for the recall is that Lot #142588, Expiration ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... revealed that 39 percent of all children in the survey ... , The survey looked at 2,505 children during the years of ... four years of age. The final result was that about ... care. Many of these children were from lower-income families and were ...
(Date:7/25/2014)... 25, 2014 A new study of participants ... which are published today in Cancer , found evidence ... 74 who had an abnormal finding on a lung cancer ... of life than did those who were screened and found ... surprise to the researchers. “We expected that participants with an ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5
... http://www.cryocath.com , Toronto Stock Exchange Symbol: CYT, ... leader in cryotherapy products to treat cardiac,arrhythmias, today announced ... Selected Third Quarter Financial and Operational Highlights: ... $9.2 million or a 12.0% increase over ...
... NANJING, China, Aug. 5 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical,Group (NYSE: ... branded generic,pharmaceuticals and manufacturer of the patented anti-cancer biotech,product ... the,quarter ended June 30, 2008., Highlights ... for the second quarter, representing ...
... Mass., Aug. 5 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ... third quarter ended June 30, 2008. The,Company will host ... am,eastern time (details follow below)., The Company reported ... $19.0 million or $0.25 per share for the quarter ...
... IRVINE, Calif., Aug. 5 SectorWatch.biz announces the,availability ... release of,articles and message boards relative to the ... aforementioned equities and the,opportunity for investors to respond ... can view MarketStats by visiting: http://www.SectorWatch.biz ,-a ...
... Goodison goes for gold and aims to give back to Mercy Ships ... ... European Laser Champion and one of Britain,s greatest medal hopes at the ... seagoing charity Mercy Ships which provides free medical care to the people ...
... age management practice, announced the opening of Cenegenics Indiana. ... leader is launching over 2008-2009. The new Cenegenics Indiana ... The center,s established protocols and personalized programs for healthy ... Minutes, 20/20, Nightline and GQ. , ...
Cached Medicine News:Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 7Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 8Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 9Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 10Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 11Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 12Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 13Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 12Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 2Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 3Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 4Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 5Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 6Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 7Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 8Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 9Health News:SectorWatch.biz Issues MarketStats for Healthy and Organic Companies ORGC, DF, WFMI, LWAY, COIN, and TOF 2Health News:Olympic Sailing Hopeful Backs Hospital Ship Charity 2Health News:Olympic Sailing Hopeful Backs Hospital Ship Charity 3Health News:Olympic Sailing Hopeful Backs Hospital Ship Charity 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: